(Q34163377)

31 July 2017

1 reference

title

Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes (English)

1 reference

31 July 2017

0 references

Garber AJ

1

1 reference

31 July 2017

publication date

1 June 2000

1 reference

Diabetes, Obesity and Metabolism

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

139-147

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Impaired effect of sulfonylurea following increased dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

An overview of metformin in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Hypoglycaemic, Antihyperglycaemic and Antidiabetic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Lactic acidosis rates in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

Comparative tolerability profiles of oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2000.00054.X

10.1046/J.1463-1326.2000.00054.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference